NIR-PIT with antibodies against PD-L1 significantly inhibited tumor growth and prolonged survival in xenograft models by activating CD8+ T cells and NK cells in the tumor microenvironment by promoting PD-L1 positive cell rupture and inhibiting tumor immunosuppressive pathways [105,106]. Here, CD8A is linked to neoplasm.